European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

PD-Podcast-DBS

The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.

The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.

Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.

“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”

For comprehensive information about Parkinson’s diagnosis please visit the EPDA website.

Go Back

Share this story

Comments


Related articles


L-dopa podcast lead

Resources & Tools

Parkinson’s podcast: L-dopa – waiting for the next act

Discussion: Why has it taken so long to improve levodopa delivery?

READ MORE
Prof Timmermann

sponsored article

Advances

Personalised and on-the-spot therapy: deep brain stimulation

Boston Scientific’s Vercise deep brain stimulation system

READ MORE
Brian Grant PTP

Agenda

February 2016

Highlights: Cycle Vietnam to Cambodia and NBA All-Star weekend

READ MORE